Navigation Links
TriLink BioTechnologies Announces Worldwide License with QuantiBact A/S, Copenhagen, Denmark
Date:5/9/2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink, www.trilinkbiotech.com), a leader in manufacturing high quality oligonucleotides, nucleoside triphosphates and mRNA, announced that it has signed a licensing agreement with QuantiBact A/S (QuantiBact, www.quantibact.com) to offer twisted intercalating nucleic acid (TINA) modified oligos.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their unique properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA may find applications wherever an enhanced Tm is required such as triplex formation or potentially even gene silencing.

"At QuantiBact we strive to make our technologies available throughout the research and diagnostic communities. We appreciate being able to work with dedicated companies that hold high recognition in the market place. The market position as well as in depth knowledge of nucleic acids embedded within TriLink will enable us to further reach our goal," says Palle Schelde , CEO, Managing Director, QuantiBact.

"At TriLink we pride ourselves on our quality and our ability to handle unique nucleic acid modifications. This makes us an ideal manufacturer of TINA oligos," stated Richard Hogrefe , Ph.D., President and CEO of TriLink. "We are excited to work with the great folks at QuantiBact and see how this technology might advance molecular diagnostics."

TINA modified oligonucleotides will be available from TriLink in June, 2013. Visit www.trilinkbiotech.com/TINA for the most up-to date information.

About QuantiBact
QuantiBact develops novel generic nucleic acid tools for research and diagnostic use. The objective of the technology is to minimize turnaround time of diagnostic procedures, increased sensitivity and fidelity of quantification. Furthermore the technology enables complex PCR multiplexing as well as utilization of crude sample material. The generic nature of the technology allows application in a broad variety of research and diagnostic applications. QuantiBact was founded on the nucleic acid intercalator research carried out at University of Southern Denmark, Odense and Hvidovre Hospital, Copenhagen. For more information, visit their website at www.quantibact.com.

About TriLink
TriLink manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, long RNA transcript synthesis and contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 50 scientists and other professionals. For more information about the firm and products, visit our web site at www.trilinkbiotech.com.

Angela Tenenini Asuncion , MBA
marketing@trilinkbiotech.com


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies Awards Keck Science Department ResearchReward
2. Leading Scientists to Debate Views on Rejuvenation Biotechnologies
3. Lifeline Biotechnologies Receives Patent for Methods to Collect and Analyze Breast Thermal Data to Determine Suspect Conditions
4. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
5. Adaptive Biotechnologies launches clonoSEQ, a more sensitive, accurate assay to detect minimal residual disease (MRD) in blood-based cancers.
6. OPX Biotechnologies Selected as Innovation Pioneer at IHS CERAWeek
7. Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement with Bristol-Myers Squibb
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, ... second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical ... eBook by providing practical tips, tools, and strategies for clinical researchers. , “The ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
Breaking Biology News(10 mins):